As biopharma companies transition therapies from clinical development to commercial supply, the need for early serialization planning becomes critical. This proactive approach helps mitigate potential supply chain disruptions that can arise during the launch phase, particularly for specialized therapies that require unique handling and distribution methods.
Incorporating serialization into broader commercial launch strategies by Phase III is vital. Companies must establish how each package will be uniquely identified, where serialization data will be generated, and how it will be shared across various partners in the supply chain. This ensures compliance with regulations such as the Drug Supply Chain Security Act (DSCSA) in the U.S., which mandates electronic tracing of prescription drugs at the package level.
Furthermore, as supply chains become increasingly complex, with multiple contract manufacturers and logistics providers involved, maintaining data integrity and visibility becomes paramount. By adopting integrated software solutions and fostering strong communication with partners, biopharma companies can navigate these challenges effectively, ensuring a smoother transition to commercial readiness.
Start your 7-day trial and see what the database can do →
